TOP FIVE HIGHLIGHTS
IVST is up 1000% YTD
IVST is up 1000% TD; from $0.02 on zero revenue to over $0.20 on $4 million revenue.
Added $4 Million sales
IVST added $4 million sales run rate YTD through growth model of acquisitions.
Pending Acquisition to add $30 Million in Revenue
LOI on Pending Acquisition to add $30 Million in revenue. CEO calls it transformational” and the first of several planned.
11.8M Shares in the Float
11.8M shares in the Float, unchanged for over two years.
No Convertible Debts, Warrants, or Options
IVST has no convertible debts, warrants, or options.
In addition to an expected 2018 annual revenue run rate of $30 Million (+) in revenue, IVST also launched a biotech division which owns a stake in the brain cancer vaccine, StemVax Glioblast (SVX-GB), including the patent number #US9764014B2 with it's investment in StemVax Therapeutics which was recently featured in the LA Business Journal in August.